ArticleJournal of toxicology2026
Nonclinical Safety Evaluation of Nonmutagenic Immunogrit Following Subacute 28-Day Repeated Dose Oral Toxicity in Sprague-Dawley Rats With GLP Compliance.
Article in Journal of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunogrit is a traditional Ayurvedic medicine prescribed to patients for their general well-being. In this study, Immunogrit was evaluated for its subacute (28 days) repeated oral dose toxicity in male and female Sprague-Dawley (SD) rats of similar age and body weight following OECD 407 guidelines under Good Laboratory Practices compliance. Mutagenic potential of Immunogrit was also evaluated through Ames assay following OECD 471 guidelines. Phytochemical profiling of the Immunogrit was performed using ultraperformance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight(UPLC/MS-QToF) tandem mass spectrometer. UPLC/MS-QToF analysis of Immunogrit identified 74 phytochemicals, well known for their health benefits. Male and female specific pathogen-free SD rats were orally gavaged to 100, 300, and 1000 mg/kg body weight/day of Immunogrit, over a period of 28 days, with two additional groups for a recovery phase of 14 days. No incidence of mortality, morbidity, or abnormal clinical signs was observed in the Immunogrit-exposed animals. Body weight, behavioral, and food consumption habit were found to be normal throughout the study period. Immunogrit exposure did not induce ophthalmic, neurological, functional, hematological, biochemical, and histopathological irregularities in animals over a period of 28 days. Latent incidence of toxicity was also not observed in the recovery group male and female rats kept under observation for an additional 14 days' post-Immunogrit exposure. Ames test of Immunogrit and its S9-treated fraction in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.